Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site warmth
Clinical narrative: warm to the touch - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide; redness - 2 inches below the injection site; a little hard - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide; sore arm - 2 inches below the injection site; swelling - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide; swollen arm; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PERIPHERAL SWELLING (swollen arm), VACCINATION SITE WARMTH (warm to the touch - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide), VACCINATION SITE ERYTHEMA (redness - 2 inches below the injection site), VACCINATION SITE INDURATION (a little hard - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide) and VACCINATION SITE PAIN (sore arm - 2 inches below the injection site) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 004M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Seafood allergy (Lobster) and Drug allergy (Midol). Concomitant products included ETHINYLESTRADIOL, NORGESTIMATE (SPRINTEC) for Birth control, FEXOFENADINE HYDROCHLORIDE (ALLEGRA) for an unknown indication.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-Jan-2021, the patient experienced PERIPHERAL SWELLING (swollen arm). On an unknown date, the patient experienced VACCINATION SITE WARMTH (warm to the touch - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide), VACCINATION SITE ERYTHEMA (redness - 2 inches below the injection site), VACCINATION SITE INDURATION (a little hard - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide), VACCINATION SITE PAIN (sore arm - 2 inches below the injection site) and VACCINATION SITE SWELLING (swelling - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. On 20-Jan-2021, PERIPHERAL SWELLING (swollen arm) had resolved. At the time of the report, VACCINATION SITE WARMTH (warm to the touch - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide), VACCINATION SITE ERYTHEMA (redness - 2 inches below the injection site), VACCINATION SITE INDURATION (a little hard - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide), VACCINATION SITE PAIN (sore arm - 2 inches below the injection site) and VACCINATION SITE SWELLING (swelling - 2 inches below the injection site - covers an area of 4 inches down my arm and is about 3.5 inches wide) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: Significant follow up appendedPatient demographics were updated.event outcome was updated.